Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Gonzalez Cao, M.Moran, T.Dalmau, J.Garcia-Corbacho, J.Bernabe, R.Juan Vidal, O. J.de Castro Carpeno, J.Blanco, R.Drozdowskyj, A.Meyerhans, A.Blanco, J.Prado, J. G.Clotet, B.Massuti Sureda, B.Provencio Pulla, M.Molina-Vila, M. A.Martinez-Picado, J.Rosell Costa, R.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27214enExtended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer groupconference outputopen access10.1016/j.annonc.2020.08.15891569-8041http://www.annalsofoncology.org/article/S0923753420415856/pdf573469101561